Responses
Clinical and epidemiological research
Concise report
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.